



VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY

**REVIEWED INTERIM SEPARATE
FINANCIAL STATEMENTS**

For the period from 01 January 2025 to 30 June 2025

October 2025

TABLE OF CONTENTS

| <u>CONTENT</u> | <u>PAGE(S)</u> |
|--|-----------------------|
| STATEMENT OF THE BOARD OF MANAGEMENT | 2 - 3 |
| REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION | 4 - 6 |
| INTERIM SEPARATE BALANCE SHEET | 7 - 8 |
| INTERIM SEPARATE INCOME STATEMENT | 9 |
| INTERIM SEPARATE CASH FLOW STATEMENT | 10 |
| NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS | 11 - 40 |

STATEMENT OF THE BOARD OF MANAGEMENT AND BOARD OF GENERAL DIRECTORS

The Board of Management of Vimedimex Medi-Pharma Joint Stock Company (Hereinafter referred to as the "Company") presents this report together with the Company's reviewed interim separate financial statements for the period from 01 January 2025 to 30 June 2025.

THE BOARD OF MANAGEMENT AND BOARD OF GENERAL DIRECTORS

Members of the Board of Management and Board of General Directors of the Company who held office during the period from 01 January 2025 to 30 June 2025 and up to the date of this report are as follows:

The Board of Management

| | | |
|----------------------------|-----------------|---------------------------|
| Mr. Le Xuan Tung | Chairman | |
| Mr. Trinh Thanh Giang | Vice Chairwoman | |
| Ms. Tran My Linh | Member | |
| Mr. Le Tri Dung | Member | |
| Mr. Le Tien Dung | Member | Appointed on 26 June 2025 |
| Mr. Nguyen Minh Son | Member | Appointed on 26 June 2025 |
| Mr. Nguyen Phan Trung Kien | Member | Appointed on 26 June 2025 |

Board of General Directors

| | | |
|---------------------|-------------------------|----------------------------|
| Ms. Tran My Linh | General Director | |
| Ms. Do Thi Dong | Deputy General Director | |
| Mr. Be Cong Son | Deputy General Director | |
| Mr. Nguyen Bao Anh | Deputy General Director | |
| Mr. Le Tri Dung | Deputy General Director | |
| Mr. Nguyen Anh Tuan | Deputy General Director | Appointed on 07 March 2025 |

Board of Supervisors

| | | |
|-----------------------------|------------------|---------------------------|
| Mr. Doan Duc Giang | Chief Supervisor | Appointed on 24 July 2025 |
| Mr. Tran Hung Cuong | Chief Supervisor | Dismissed on 26 June 2025 |
| Mr. Truong Duy Phong | Member | Appointed on 26 June 2025 |
| Ms. Nguyen Thanh Thanh Binh | Member | Appointed on 26 June 2025 |
| Mr. Nguyen Ba Tuan | Member | Dismissed on 26 June 2025 |

The legal representative of the Company during the accounting period and up to the date of this report is Ms. Tran My Linh - General Director.

EVENTS AFTER THE REPORTING PERIOD

The Board of Management and the Board of General Directors of the Company confirm that, except for the information disclosed in Note 33 to the Notes to the financial statements, there were no other events arising after 30 June 2025 that have a material impact and require adjustment to or disclosure in the interim financial statements for the period from 01 January 2025 to 30 June 2025 attached hereto.

**STATEMENT OF THE BOARD OF MANAGEMENT AND BOARD OF GENERAL DIRECTORS
(CONT'D)**

THE AUDITOR

The interim separate financial statements for the period from 01 January 2025 to 30 June 2025 have been reviewed by UHY Auditing and Consulting Company Limited.

RESPONSIBILITY OF THE BOARD OF MANAGEMENT AND THE BOARD OF GENERAL DIRECTORS

The Board of Management of the Company is responsible for preparing the interim separate financial statements, which give a true and fair view of the Company's financial position as at 30 June 2025, its results of operation and cash flows for the period from 01 January 2025 to 30 June 2025. In preparing those interim separate financial statements, the Board of Management and the Board of General Directors are required to:

- Select suitable accounting policies and apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting principles have been followed, subject to any material departures disclosed and explained in the interim separate financial statements;
- Design and implement an effective system of internal control to ensure preparation and fair presentation of the financial statements in order to limit risks and frauds; and
- Prepare the interim separate financial statements on a going concern basis unless it is inappropriate to presume that the Company will continue its business.

The Board of Management and the Board of General Directors confirm that the Company has complied with the above requirements in preparing the interim separate financial statements.

The Board of Management and the Board of General Directors are responsible for ensuring that proper accounting records are kept, which disclose, with reasonable accuracy at any time, the financial position of the Company and to ensure that the interim separate financial statements comply with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and other related legal regulations on preparation and presentation of the financial statements. It is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Board of Management and the Board of General Directors confirm that the Company has fully complied with its regulatory disclosure obligations as stipulated in Circular No. 96/2020/TT-BTC, dated 16 November 2020, issued by the Ministry of Finance, and Circular No. 68/2024/TT-BTC, dated 18 September 2024, amending and supplementing certain provisions of Circular No. 96/2020/TT-BTC concerning information disclosure in the securities market. The Company also ensures full compliance with the provisions of Decree No. 155/2020/ND-CP, dated 31 December 2020, issued by the Government, which provides detailed guidance on the implementation of specific provisions of the Securities Law. Furthermore, the Company adheres to the corporate governance requirements outlined in Circular No. 116/2020/TT-BTC, dated 31 December 2020, issued by the Ministry of Finance, which specifies governance standards applicable to public companies under Decree No. 155/2020/ND-CP.

For and on behalf of the Board of Management and the Board of General Directors,



Tran My Linh
General Director

Hanoi, 30 October 2025

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

**To: Shareholders, Board of Management and Board of General Directors of
Vimedimex Medi-Pharma Joint Stock Company**

We have reviewed the accompanying interim separate financial statements of Vimedimex Medi-Pharma Joint Stock Company ("the Company"), which is prepared on 30 October 2025, from page 7 to page 40 that includes interim separate balance sheet as at 30 June 2025, interim separate income statement and interim separate cash flow statement for the period from 01 January 2025 to 30 June 2025 and Notes to the interim separate financial statements.

Responsibilities of the Board of Management and Board of General Directors

The Board of Management and Board of General Directors of the Company are responsible for the preparation and fair presentation of the interim separate financial statements in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and related legal regulations on the preparation and presentation of the interim separate financial statements and for such internal control as the Board of Management and Board of General Directors determine is necessary to enable the preparation and presentation of the interim separate financial statements that are free from material misstatements, whether due to fraud or error.

Responsibilities of Auditors

Our responsibility is to express a conclusion on the interim separate financial statements based on our review. We conducted our review in accordance with the Vietnamese Standard on Review Engagements 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of interim financial information consists primarily of inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for qualified conclusion

According to the Minutes of the Board of Management's Meeting No. 15/2025/BBHQDT-VMD dated 20 September 2025 of Vimedimex Medi-Pharma Joint Stock Company, the Board of Management requested the Board of General Directors to implement necessary measures to recover the losses incurred by the Company, totaling VND 131,797,789,132, comprising VND 48,139,850,632 of losses from office leasing cash flows of the buildings located at 246 Cong Quynh Street and 45 Vo Thi Sau Street for the period from 2021 to 2024; and VND 83,657,938,500 of understated pharmaceutical distribution service revenue of Vimedimex Binh Duong for the period from 2021 to 2024. As of the date of issuance of this Report, no results have been obtained from the implementation of the above-mentioned loss recovery measures in accordance with the said Minutes of the Board of Management's Meeting. Therefore, we have not been able to assess the necessary adjustments (if any) that may affect the Company's interim separate financial statements.

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION (CONT'D)

Qualified conclusion

Based on our review, except for the possible effects of the matters described in the “Basis for Qualified conclusion” section, nothing has come to our attention that causes us to believe that the accompanying interim separate financial statements do not present fairly, in all material respects, the financial position of Vimedimex Medi-Pharma Joint Stock Company as at 30 June 2025, and its results of operations and cash flows for the period from 1 January 2025 to 30 June 2025, in accordance with Vietnamese Accounting Standards, the Vietnamese Corporate Accounting System, and the related legal regulations on the preparation and presentation of interim separate financial statements.

Emphasis of matter

We draw attention to Note 21 to the interim separate financial statements, which states that on 26 June 2025, pursuant to Resolution No. 01/2025/NQ-ĐHĐCĐ-VMD of the General Meeting of Shareholders of Vimedimex Medi-Pharma Joint Stock Company, the General Meeting approved the revocation of 2,284,950 VMD shares, representing 14.8% of the charter capital of Vimedimex Medi-Pharma Joint Stock Company, and the cancellation of shareholder status of Ms. Nguyen Ngoc Dung, Ms. Tran Thi Doan Trang, and Mr. Tran Kien Cuong, effective from 1 January 2025. The resolution also confirmed the shareholder status of Vimedimex Pharmaceutical Group Joint Stock Company as the holder of 2,284,950 VMD shares, equivalent to 14.8% of the charter capital of Vimedimex Medi-Pharma Joint Stock Company, effective from 1 January 2025.

We draw attention to Note 33 to the interim separate financial statements, which discloses the following matters:

- The Board of Management of Vimedimex Medi-Pharma Joint Stock Company (VMD) requested the Board of General Directors to implement measures to assist in the recovery of losses incurred by Vimedimex Pharmaceutical Group Joint Stock Company (VMG), a related party of VMD. These losses include fund transfers from VMG through VMD, followed by cash withdrawals and bank transfers totaling VND 343,738,865,391 (*during the period from 15 April 2021 to 30 January 2023*), and a receivable from Ms. Nguyen Ngoc Dung amounting to VND 193 billion, representing cash withdrawn in 2022 but not yet repaid (*according to the Minutes of the Board of Management' Meeting No. 136/2024/BB-VMG dated 31 December 2024 of VMG, the Board of Management of VMG approved that VMG would be responsible for recovering the doubtful receivable of VND 193 billion related to Ms. Nguyen Ngoc Dung on behalf of VMD, and accordingly, VMD would no longer have any obligation to repay the VND 193 billion liability to VMG.*)
- Certain individuals in executive management positions at both VMG and VMD directed cash inflows and outflows totaling VND 252,353,295,174, and instructed Mr. Nguyen Tien Manh to withdraw VND 76,978,900,000, resulting in a total loss of VND 328,400,200,202 for VMG during the period from 19 April 2021 to 24 October 2024.

We draw attention to Note 34 to the interim separate financial statements, which describes that the Company has cooperated with certain investors to develop the Citilight Building located at 45 Vo Thi Sau Street, District 1 (former), Ho Chi Minh City. Upon completion, the Company allocated floor areas to investors in accordance with the proportions stipulated in the business cooperation contracts. On 24 February 2020, the Company issued Official Letter No. 1421/2020/CV-VMD providing official information to the press agencies regarding the Citilight Building at 45 Vo Thi Sau Street. Accordingly, the Company temporarily suspended activities related to the distribution of rental income from the commercial areas of the Citilight Building, as well as other related activities, in order to review the entire capital contribution process, settlement of construction costs, allocation of floor areas, management and operation, and profit distribution of the Citilight Building. The Company and the investors are currently in discussions to reach an agreement on the above matters. Consequently, this event may result in future economic benefits and/or obligations for the Company.

Our qualified conclusion is not modified in respect of this matter.

**REPORT ON REVIEW
OF INTERIM FINANCIAL INFORMATION (CONT'D)**

Other matter

The interim separate financial statements for the period from 1 January 2024 to 30 June 2024 were reviewed, and the separate financial statements for the financial year ended 31 December 2024 were audited by another independent auditor and audit firm. That auditor and audit firm expressed an unqualified conclusion on the interim separate financial statements for the period from 1 January 2024 to 30 June 2024 in their Review Report No. 0208.1/2024/BCSX/IAV dated 29 August 2024, and expressed an unqualified opinion on the separate financial statements for the financial year ended 31 December 2024 in their Audit Report No. 0208.1/2024/BCTC/IAV dated 31 March 2025.



Pham Gia Dat

Deputy General Director

Auditor's Practicing Certificate

No. 0798-2023-112-1

For and on behalf of

UHY AUDITING AND CONSULTING COMPANY LIMITED

Hanoi, 30 October 2025

For the period from 01/01/2025 to 30/06/2025

INTERIM SEPARATE BALANCE SHEET

As at 30 June 2025

| ASSETS | Codes | Note | 30/06/2025 VND | 01/01/2025 VND |
|---|------------|-----------|------------------------|------------------------|
| CURRENT ASSETS | 100 | | 481,028,076,908 | 453,194,972,722 |
| Cash and cash equivalents | 110 | 5 | 36,275,558,425 | 186,536,771,380 |
| Cash | 111 | | 14,275,558,425 | 10,636,771,380 |
| Cash equivalents | 112 | | 22,000,000,000 | 175,900,000,000 |
| Short-term investments | 120 | 6 | 175,900,000,000 | - |
| Held-to-maturity investments | 123 | | 175,900,000,000 | - |
| Current accounts receivable | 130 | | 257,888,627,591 | 255,534,446,806 |
| Short-term trade receivables | 131 | 7 | 185,842,080,707 | 185,906,451,483 |
| Short-term advances to suppliers | 132 | 8 | 6,802,545,353 | 7,318,338,859 |
| Other short-term receivables | 136 | 9 | 149,740,083,512 | 146,805,738,445 |
| Provision for doubtful short-term receivables | 137 | 7, 8, 9 | (84,496,081,981) | (84,496,081,981) |
| Inventories | 140 | 10 | 9,055,873,622 | 9,055,873,622 |
| Inventories | 141 | | 9,380,971,790 | 9,380,971,790 |
| Provision for devaluation of inventories | 149 | | (325,098,168) | (325,098,168) |
| Other current assets | 150 | | 1,908,017,270 | 2,067,880,914 |
| Short-term prepaid expenses | 151 | | 51,656,137 | 166,982,523 |
| Value-added tax deductible | 152 | | 1,856,361,133 | 1,900,898,391 |
| NON-CURRENT ASSETS | 200 | | 332,097,883,158 | 334,576,027,767 |
| Long-term receivables | 210 | | 5,714,576,965 | 5,714,576,965 |
| Other long-term receivables | 216 | 9 | 5,714,576,965 | 5,714,576,965 |
| Fixed assets | 220 | | 17,968,654,186 | 18,481,793,649 |
| Tangible fixed assets | 221 | 11 | 2,575,511,651 | 2,856,177,712 |
| - Cost | 222 | | 33,496,802,534 | 33,496,802,534 |
| - Accumulated depreciation | 223 | | (30,921,290,883) | (30,640,624,822) |
| Intangible fixed assets | 227 | 12 | 15,393,142,535 | 15,625,615,937 |
| - Costs | 228 | | 22,977,113,159 | 22,977,113,159 |
| - Accumulated amortization | 229 | | (7,583,970,624) | (7,351,497,222) |
| Investment property | 230 | 13 | 59,276,308,205 | 60,742,297,625 |
| - Costs | 231 | | 103,327,212,088 | 103,327,212,088 |
| - Accumulated depreciation | 232 | | (44,050,903,883) | (42,584,914,463) |
| Long-term assets in progress | 240 | | 33,506,151,377 | 32,752,816,333 |
| Construction in progress | 242 | 14 | 33,506,151,377 | 32,752,816,333 |
| Long-term investments | 250 | 15 | 214,958,388,968 | 214,958,388,968 |
| Investments in subsidiaries | 251 | | 207,027,132,620 | 207,027,132,620 |
| Investment in other entities | 253 | | 18,730,978,694 | 18,730,978,694 |
| Provision for long-term investments | 254 | | (10,799,722,346) | (10,799,722,346) |
| Other long-term assets | 260 | | 673,803,457 | 1,926,154,227 |
| Long-term prepaid expenses | 261 | | 673,803,457 | 1,926,154,227 |
| TOTAL ASSETS | 270 | | 813,125,960,066 | 787,771,000,489 |

For the period from 01/01/2025 to 30/06/2025

INTERIM SEPARATE BALANCE SHEET (CONT'D)

As at 30 June 2025

| RESOURCES | Code | Note | 30/06/2025 VND | 01/01/2025 VND |
|---|------------|-----------|------------------------|------------------------|
| LIABILITIES | 300 | | 479,160,665,599 | 461,310,355,052 |
| Current liabilities | 310 | | 460,447,612,432 | 443,667,262,660 |
| Short-term trade payables | 311 | 16 | 235,089,736,755 | 219,835,038,890 |
| Short-term advances from customers | 312 | 17 | 166,859,295,475 | 166,873,354,819 |
| Tax and other payables to the State budget | 313 | 20 | 1,856,944,648 | 2,879,812,848 |
| Payables to employees | 314 | | 410,546,771 | 392,618,724 |
| Short-term accrued expenses | 315 | 18 | 939,918,883 | 1,249,079,997 |
| Other short-term payables | 319 | 19 | 50,206,558,754 | 47,352,746,236 |
| Bonus and welfare fund | 322 | | 5,084,611,146 | 5,084,611,146 |
| Non-current liabilities | 330 | | 18,713,053,167 | 17,643,092,392 |
| Other long-term payables | 337 | 19 | 18,713,053,167 | 17,643,092,392 |
| OWNER'S EQUITY | 400 | | 333,965,294,467 | 326,460,645,437 |
| Capital | 410 | 21 | 332,041,834,527 | 324,537,185,497 |
| Share capital | 411 | | 154,402,680,000 | 154,402,680,000 |
| - Shares with voting rights | 411a | | 154,402,680,000 | 154,402,680,000 |
| Share premiums | 412 | | 114,168,390,910 | 114,168,390,910 |
| Investment and development fund | 418 | | 29,732,320,126 | 29,732,320,126 |
| Other equity funds | 420 | | 7,338,446,765 | 7,338,446,765 |
| Retained earnings | 421 | | 26,399,996,726 | 18,895,347,696 |
| - Accumulated losses by the end of prior year | 421a | | 18,895,347,696 | - |
| - Retained earnings for the current period | 421b | | 7,504,649,030 | 18,895,347,696 |
| Other funds | 430 | | 1,923,459,940 | 1,923,459,940 |
| Funding source | 431 | | 1,923,459,940 | 1,923,459,940 |
| TOTAL LIABILITIES AND OWNERS' EQUITY | 440 | | 813,125,960,066 | 787,771,000,489 |

Hanoi, 30 October 2025



Tran Thi Thanh Binh
Preparer



Nguyen Thi Thu Dung
Chief Accountant



Tran My Linh
General Director

For the period from 01/01/2025 to 30/06/2025

INTERIM SEPARATE INCOME STATEMENT

For the period from 01 January 2025 to 30 June 2025

| ITEMS | Code | Note | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|---|------|------|---|---|
| Revenue from sale of goods and rendering of services | 01 | | 44,727,903,997 | 43,198,600,122 |
| Deductions | 02 | | - | - |
| Net revenue from sale of goods and rendering of services | 10 | 23 | 44,727,903,997 | 43,198,600,122 |
| Cost of goods sold | 11 | 24 | 24,845,684,316 | 26,116,584,389 |
| Gross profit from sale of goods and rendering of services | 20 | | 19,882,219,681 | 17,082,015,733 |
| Financial income | 21 | 25 | 4,193,407,007 | 2,257,639,707 |
| Financial expenses | 22 | 26 | 3,019,868,847 | 4,016,655,835 |
| Selling expenses | 25 | 27 | 6,167,555,882 | 7,172,262,483 |
| General and administrative expenses | 26 | 27 | 5,534,618,375 | 4,740,089,275 |
| Net profits from operating activities | 30 | | 9,353,583,584 | 3,410,647,847 |
| Other income | 31 | 28 | 308,161,398 | 4,862,295 |
| Other expenses | 32 | 29 | 222,319,788 | 66,103,046 |
| Other profit | 40 | | 85,841,610 | (61,240,751) |
| Accounting profit before tax | 50 | | 9,439,425,194 | 3,349,407,096 |
| Current corporate income tax expense | 51 | 31 | 1,934,776,164 | 674,602,029 |
| Net profit after tax | 60 | | 7,504,649,030 | 2,674,805,067 |

Hanoi, 30 October 2025



Tran Thi Thanh Binh
Preparer



Nguyen Thi Thu Dung
Chief Accountant



Tran My Linh
General Director

For the period from 01/01/2025 to 30/06/2025


INTERIM SEPARATE CASH FLOW STATEMENT


(Applying indirect method)

For the period from 01 January 2025 to 30 June 2025

| ITEMS | Codes | Note | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|-----------|----------|---|---|
| I. Cash flows from operating activities | | | | |
| <i>Profit before tax</i> | 01 | | 9,439,425,194 | 3,349,407,096 |
| Adjustments for: | | | | |
| Depreciation and amortization | 02 | | 1,979,128,883 | 2,043,206,939 |
| Foreign exchange (gains)/losses arisen from revaluation of monetary accounts denominated in foreign currency | 04 | | 2,204,400,799 | 4,016,655,835 |
| Gains (losses) on investing activities | 05 | | (4,193,407,007) | (2,257,639,707) |
| Operating profit before movements in working capital | 08 | | 9,429,547,869 | 7,151,630,163 |
| (Increase)/decrease in receivables | 09 | | 389,807,158 | 2,464,412,519 |
| Increase/(decrease) in payables (excluding interest, corporate income tax) | 11 | | 16,005,725,572 | 12,806,339,236 |
| (Increase)/decrease in prepaid expenses | 12 | | 1,367,677,156 | 2,134,430,433 |
| Corporate income tax paid | 15 | | (2,294,591,988) | (1,870,173,752) |
| Net cash flows from operating activities | 20 | | 24,898,165,767 | 22,686,638,599 |
| II. Cash flows from investing activities | | | | |
| Acquisition of fixed assets and other long - term assets | 21 | | (753,335,044) | (4,302,223,292) |
| Loans and purchase of debt instruments from other entities | 23 | | (175,900,000,000) | - |
| Interest and dividend received | 27 | | 1,493,956,322 | 2,257,639,707 |
| Net cash flows from investing activities | 30 | | (175,159,378,722) | (2,044,583,585) |
| III. Cash flows from financing activities | | | | |
| Dividends and profit paid to owner | 36 | | - | (8,301,300) |
| Net cash flows from financing activities | 40 | | - | (8,301,300) |
| Net cash flows during the period | 50 | | (150,261,212,955) | 20,633,753,714 |
| Opening balance of cash and cash equivalents | 60 | 5 | 186,536,771,380 | 166,927,426,964 |
| Impacts of exchange rate fluctuations | 61 | | - | - |
| Closing balance of cash and cash equivalents | 70 | 5 | 36,275,558,425 | 187,561,180,678 |

Hanoi, 30 October 2025


Tran Thi Thanh Binh
Preparer


Nguyen Thi Thu Dung
Chief Accountant


Tran My Linh
General Director



For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

1. GENERAL INFORMATION

1.1. OWNERSHIP STRUCTURE

Vimedimex Medi-Pharma Joint Stock Company established and operating under Enterprise Registration Certificate No. 0300479760, initially issued by Hanoi City Department of Finance (formerly Department of Planning and Investment) on 12 June 2006 and amended for the 36th time on 27 March 2023.

The registered head office of the Company is located on the 8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam.

The Company's charter capital as stated in the Business Registration Certificate is VND 154,402,680,000 (*One hundred fifty-four billion, four hundred two million, six hundred eighty thousand dong*). Total number of shares is 15,440,268 shares, par value of 01 (one) share is VND 10,000.

The total number of employees of the Company as at 30 June 2025 was 31 (as at 01 January 2025: 33).

1.2. BUSINESS LINES AND PRINCIPAL ACTIVITIES

The Company operates principally in the fields of trading, services, and real estate business.

The Company's principal business activities include:

- Acting as an entrusted agent for import and export services;
- Leasing office buildings and warehouses.

1.3. NORMAL OPERATING CYCLE

The Company's normal operating cycle is carried out within a period not exceeding 12 months.

1.4. COMPANY STRUCTURE

As of 30 June 2025, the Company had the following branches:

| Company name | Place of establishment and operation | Ownership ratio | Voting rights ratio | Main operation field |
|--|--------------------------------------|-----------------|---------------------|--|
| Vimedimex Pharmaceutical LLC., | Ho Chi Minh | 100% | 100% | Wholesale of pharmaceutical products, pharmaceuticals, functional foods, medical equipment, cosmetics, and consumer goods for mothers and children |
| Vimedimex Binh Duong One Member Co.,LTD | Binh Duong | 100% | 100% | Wholesale and retail of pharmaceutical products, business cooperation, medical examination and treatment |
| Vimedimex Pharmaceutical Distribution Center Co.,LTD | Hanoi | 55.6% | 55.6% | Wholesale, retail of pharmaceutical products, business cooperation, medical examination and treatment |

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

1. GENERAL INFORMATION (CONT'D)

1.4. COMPANY STRUCTURE (CONT'D)

As at 30 June 2025, the Company has the following affiliated units:

| Affiliated unit name | Place of establishment and operation | Main operation field |
|--|--------------------------------------|---|
| Hanoi branch | Hanoi | Trade and distribution of pharmaceutical products |
| Da Lat Center for Research on Cultivation and Processing of Medicinal Plants (*) | Da Lat | Cultivation of medicinal plants |

(*) The Da Lat Research Center for Medicinal Plant Cultivation and Processing has currently ceased operations.

2. ACCOUNTING PERIOD, UNIT OF CURRENCY USED IN FINANCIAL STATEMENTS.

2.1. ACCOUNTING PERIOD

The financial year of the Company begins from 01 January to 31 December.

The separate financial statements being attached have been prepared for the period from 01 January 2025 to 30 June 2025.

2.2. UNIT OF CURRENCY OF THE SEPARATE FINANCIAL STATEMENTS

The accounting currency used in accounting records and in the preparation of these interim separate financial statements is Vietnamese Dong (VND).

3. ACCOUNTING STANDARDS

3.1. STATEMENT OF COMPLIANCE WITH ACCOUNTING STANDARDS AND ACCOUNTING SYSTEM

The separate financial statements for the period from 01 January 2025 to 30 June 2025 are prepared in accordance with the Vietnamese Corporate Accounting System issued under Circular No. 200/2014/TT-BTC dated 22 December 2014 by the Ministry of Finance and Circular No. 53/2016/TT-BTC dated 21 March 2016 by the Ministry of Finance amending and supplementing certain articles of Circular No. 200/2014/TT-BTC.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

3. ACCOUNTING STANDARDS (CONT'D)

3.1. STATEMENT OF COMPLIANCE WITH ACCOUNTING STANDARDS AND ACCOUNTING SYSTEM (CONT'D)

The Board of Management and Board of General Directors of the Company ensure full compliance with requirements of Vietnamese Accounting Standards and Vietnamese Corporate Accounting System for the preparation of the separate financial statements.

3.2. BASIS OF PREPARATION SEPARATE FINANCIAL STATEMENTS

The Company's interim separate financial statements are prepared on an accrual basis in accordance with the historical cost principle.

Users of the interim separate financial statements are advised to review the consolidated financial statements of the company in addition to the financial statements for the period from 01 January 2025 to 30 June 2025, to obtain comprehensive information regarding the financial positions, results of operations, and cash flow of the entity.

3.3. ACCOUNTING METHOD

The Company applies the computerized accounting system.

4. ACCOUNTING POLICIES

The following accounting policies are the foundation in preparing the interim separate financial statements for the period from 01 January 2025 to 30 June 2025.

4.1. CHANGES IN ACCOUNTING POLICIES AND NOTES

The accounting policies used by the Company in preparing the interim separate financial statements for the period from 01 January 2025 to 30 June 2025 are consistent with those applied for preparing the separate financial statements for the year ended 31 December 2024.

4.2. ACCOUNTING ESTIMATES

The preparation of the separate financial statements in conformity with Vietnamese Accounting Standards requires the Board of General Directors to make estimates and assumptions that affect the reported amounts of liabilities, assets, and the disclosure of contingent liabilities and assets as at the reporting date, as well as the reported amounts of revenue and expenses during the financial year (operating period). Actual results may differ from those estimates and assumptions.

4.3. CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash on hand, demand deposits at banks, deposits, and guarantees, as well as short-term investments with an original maturity of no more than 3 months, which are highly liquid, easily convertible into a known amount of cash, and subject to insignificant risk of changes in value.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

4. ACCOUNTING POLICIES (CONT'D)

4.4. RECEIVABLES AND PROVISIONS FOR DOUBTFUL RECEIVABLES

Receivables are presented at their carrying amounts, net of provision for doubtful debts.

The classification of receivables is based on the following principles:

- Trade receivables represent amounts receivable arising from commercial transactions related to the sale of goods and services between the Company and independent buyers.
- Other receivables represent non-commercial receivables that are not related to purchase and sale transactions.
- Provision for doubtful debts is made by the Company for receivables that are overdue for payment as stipulated in economic contracts, contractual commitments, or debt acknowledgment letters, for which the Company has made repeated collection attempts but has not yet recovered the debts. The determination of the overdue period for such receivables is based on the original payment terms stated in the initial sales or purchase contracts, excluding any extensions of payment terms agreed upon between the parties. In addition, the provision is also made for receivables that are not yet due for payment but where the debtors have gone bankrupt, are in the process of dissolution, have gone missing, or have absconded. The provision shall be reversed when the debts are subsequently recovered.
- Any increase or decrease in the provision for doubtful debts as at the reporting date is recognized in general and administrative expenses.

4.5. INVENTORIES

Inventories are stated at the lower of cost and net realizable value. The cost of inventory includes the costs of bringing the inventories to their present location and condition, including: purchase price, non-refundable taxes, costs of transportation, loading and unloading, storage during purchase, normal loss, and other costs directly attributable to the purchase of inventory.

Net realizable value is the estimated selling price of inventories in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

Inventories are valued using the weighted average method and accounted for under the perpetual inventory system.

The Company's provision for inventory devaluation is made in accordance with prevailing regulations. Accordingly, the Company is allowed to make provisions for devaluation of inventories when the original cost of inventory is higher than the net realizable value at the end of the accounting period.

4.6. PREPAID EXPENSES

Expenses incurred in relation to the operating results of multiple financial years are recognised as prepaid expenses and gradually allocated to the profit or loss over subsequent financial years.

The calculation and allocation of long-term prepaid expenses into production and business costs in each accounting period is based on the nature and level of each type of expense to select a reasonable allocation method and criteria.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

4. ACCOUNTING POLICIES (CONT'D)

4.6. PREPAID EXPENSES (CONT'D)

The Company's prepaid expenses include the value of tools and supplies awaiting allocation, fixed asset repair costs, office repair and completion costs and other costs, which are considered to be able to provide future economic benefits to the Company. These costs are capitalized as prepayments and allocated to the income statement using the straight-line method in accordance with current regulations.

4.7. TANGIBLE FIXED ASSETS AND DEPRECIATION

Tangible fixed assets are recorded at historical cost, presented on the balance sheet in cost, accumulated depreciation and carrying amount.

The recognition of tangible fixed assets and depreciation of fixed assets in compliance with Vietnam Accounting Standard No. 03 - Tangible fixed assets, Circular No. 200/2014/TT-BTC dated 22 December 2014 issued by the Ministry of Finance providing guidance on the Vietnamese Corporate Accounting System.

Tangible fixed assets are presented as cost and accumulated depreciation. The historical cost of tangible fixed assets includes the purchase price and all directly attributable expenses incurred to bring the asset to a working condition for its intended use. The cost of tangible fixed assets built by contractors includes the value of the completed handover, directly related costs (if any).

Tangible fixed assets are depreciated on a straight-line method based on estimated useful life. The specific depreciation periods are as follows:

| Assets | Useful life (year) |
|------------------------------------|--------------------|
| - Building, structure and property | 05 – 25 |
| - Machinery, equipment | 05 - 08 |
| - Transportation vehicles | 06 - 10 |
| - Office, administrative equipment | 03 - 08 |
| - Perennial plants | 06 |
| - Others | 04 - 25 |

4.8. INTANGIBLE FIXED ASSETS AND AMORTIZATION

Intangible fixed assets are recorded at historical cost, and presented on the balance sheet under cost, accumulated amortization and carrying amount.

The recognition and amortization of intangible fixed assets are carried out in accordance with Vietnamese Accounting Standard No. 04 - Intangible fixed assets, Circular No. 200/2014/TT-BTC dated 22 December 2014 of the Ministry of Finance providing guidance on the Vietnamese Corporate Accounting System.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

4. ACCOUNTING POLICIES (CONT'D)

4.8. INTANGIBLE FIXED ASSETS AND AMORTIZATION (CONT'D)

The cost of intangible fixed assets includes all expenses incurred by the Company to acquire the assets up to the time the assets are ready for use. Subsequent expenses related to intangible fixed assets are recognized as operating expenses in the period unless these expenses are associated with a specific intangible fixed asset and enhance the economic benefits derived from the assets.

Fixed assets are presented at cost less accumulated depreciation. These comprise management-related software, which are amortized over their estimated useful lives ranging from 3 to 48 years.

4.9. INVESTMENT PROPERTY

The right to utilize land, a house, a portion of a house, or infrastructure that is possessed by the Company for the purpose of earning income through rental or capital appreciation is referred to as investment property. Investment property is stated at its historical cost, minus the accumulated depreciation. The historical cost of investment property is the total cost that the Company is required to pay or the fair value of the consideration given to acquire the investment property up to the time of purchase or completion of construction.

These expenses are documented as an increase in historical cost unless it is anticipated that they will generate a greater economic benefit for the investment real estate in the future than the initial, assessed level of performance. Expenses associated with investment real estate that occur subsequent to initial recognition are recorded.

When investment properties are sold, the cost and accumulated depreciation are written off, and any resulting gain or loss is recognized as income or expense in the period.

Transfers from owner-occupied property or inventories to investment property are effected exclusively when the proprietor ceases to use the property and commences leasing it to another party or at the conclusion of the construction phase. Transfers from investment property to owner-occupied property or inventories happen exclusively when the proprietor commences to utilize the property or to develop it with the intention of selling it. Transfers from investment property to owner-occupied property or inventories do not alter the cost or carrying amount of the property at the time of the transfer.

The straight-line method is applied to depreciate investment properties that are used for rental purposes over their anticipated useful lives. The anticipated useful lives of specific investment properties are as follows:

| Assets | Useful life (year) |
|------------------------------------|--------------------|
| - Building, structure and property | 24 - 25 |
| - Land use rights | 50 |

4.10. FINANCIAL INVESTMENTS

Held-to-maturity financial investments include: Term bank deposits, bonds, preferred shares that the issuer is obligated to repurchase at a specific future date, loans, and other investments held to maturity for the purpose of earning periodic interest.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

4. ACCOUNTING POLICIES (CONT'D)

4.10. FINANCIAL INVESTMENTS (CONT'D)

Investments in other entities refer to equity investments in entities where the Company does not have control, joint control, or significant influence over the investee.

Subsidiaries are companies that are controlled by the Company. Control is accomplished when the Company has the authority to regulate the financial and operational policies of an investee company in order to capitalize on its operations.

The Company initially recognizes its investment in the Subsidiary at cost. The Company records in the income statement the portion of profit distributed from the accumulated net profit of the investee arising after the investment date. Other amounts received by the Company, apart from the distributed profit, are considered recoveries of the investment and are recognized as a deduction from the cost of the investment.

Provision for impairment of investments

Provision for impairment of investments in equity instruments of other entities is made at the time of preparation of the separate financial statements when such investments show a decline compared to their original cost. The Company makes provision for impairment as follows:

- The provision is based on the market value of the shares for investments in listed shares or for which the fair value of the investment is reliably determined.
- Provisions are made for investments whose fair value cannot be determined at the reporting date in an amount that is equivalent to the difference between the actual capital contributions of the parties at other entities and the actual equity multiplied by the company's capital contribution ratio in comparison to the total actual capital contributions of the parties at other entities.

In case an investment entity is obligated to prepare the consolidation of financial statements, the foundation for establishing the loss provision is the consolidated financial statements.

Adjustments for provision in financial investments to other entities must be identified at the closing date of financial statements and recognized in the income statement as financial expenses or income.

4.11. LIABILITIES AND ACCRUED EXPENSES

Payables and accrued expenses are recognized for future amounts payable in relation to goods and services received. Accrued expenses are recognized based on reasonable estimates of the amounts payable.

The classification of payables as trade payables, accrued expenses and other payables is carried out according to the following principles:

- Trade payables reflect payables of commercial transactions from the purchase of goods, services, assets where the supplier is an independent entity from the Company, including payables from imports through trustees.
- Accrued expenses reflect amounts payable for goods and services received from suppliers or provided to customers but not yet paid due to a lack of invoices or insufficient accounting records and documents and amounts payable to employees in terms of leave wages, operating expenses deducted in advance.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

- Other payables reflect payables that are non-commercial in nature, unrelated to the purchase, sale or provision of goods and services.

4.12. OWNER'S EQUITY

Owner's equity is recognized according to the actual amount of capital contributed by shareholders.

Undistributed profit after tax reflects the business results (profit or loss) after corporate income tax and the distribution or settlement of losses by the Company. The distributable accumulated earnings are required to not exceed the undistributed profit after tax in the consolidated financial statements after the impact of profits recorded from bargain purchases has been excluded. Retained earnings are the property of shareholders; however, the decision to retain them, distribute them or distributable amount to shareholders through dividends will be determined by the company's charter, comply with Vietnamese law and approved by the General Meeting of Shareholders.

4.13. REVENUE

Revenue is recognized when it is probable that the economic benefits will flow to the company and can be reliably measured. Net revenue is measured at the fair value of the amounts received or receivable after deducting trade discounts, sales rebates, and sales return. Revenue is recognized when the following conditions are simultaneously satisfied:

Revenue from rendering of services

Revenue from rendering of services is recognized when all the following conditions are simultaneously met:

- Revenue is determined with relative certainty;
- Ability to derive economic benefits from the transaction of providing such services;
- Determine the part of work completed on the date of preparation of the balance sheet;
- Determine the costs incurred for the transaction and the cost to complete the transaction to provide that service.

The extent of service work finished is established by the approach used to evaluate the completed tasks.

Revenue from financial activities

Revenue arising from interest, royalties, dividends, profit distributions, and other financial income is recognized when both of the following conditions are satisfied:

- It is probable that the economic benefits associated with the transaction will flow to the Company;
- The revenue can be measured reliably.

4.14. COST OF GOODS SOLD

The cost of goods sold in the year is recorded in accordance with the revenue generated in the period and ensures compliance with the prudence principle. Cases of abnormal losses, expenses in excess of normal levels, and lost inventories after excluding the responsibilities of relevant collectives and individuals,... are fully and promptly recorded in the cost of goods sold for the period.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

4. ACCOUNTING POLICIES (CONT'D)

4.15. FINANCE EXPENSES

Finance expenses include losses incurred from foreign currency sales, foreign exchange losses, and other related items.

These expenses are recorded at their total amounts incurred during the period and are not offset against financial income.

4.16. TAXATION

Input value-added tax (VAT) is accounted for using the deduction method.

Current tax payable is calculated based on taxable income for the year. Taxable income may differ from accounting profit before tax presented in the income statement as it excludes taxable or deductible income and expenses in other years (including carryforward losses, if any) and non-taxable or non-deductible items.

The current corporate income tax rate is 20%.

Taxable profit is determined based on the business results after adjustment for non-taxable income and non-deductible expenses. The determination of the current taxable profit and corporate income tax payable is based on prevailing tax regulations. However, these regulations are subject to periodic variation and their ultimate determination depends on the results of tax authorities' examination.

Other taxes are in accordance with the prevailing regulations by the State.

4.17. RELATED PARTIES

Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial and operating decisions. Related parties include:

- Enterprises have the right to control or be directly or indirectly controlled by one or more intermediaries, joint ventures, associates, or jointly controlled entities;
- Individuals have the right to vote in reported enterprises, having a significant influence directly or indirectly on these enterprises, key management have the authority and responsibility for making plans, managing and controlling activities of the Company, including close family members of these individuals;
- Enterprises owned by the aforementioned individuals, having direct or indirect voting rights or having a significant influence on the business.

When considering each related party relationship, attention is paid to the nature of the relationship, not just its legal form. Accordingly, all transactions and balances with related parties are disclosed by the Company in the notes below.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

5. CASH AND CASH EQUIVALENTS

| | 30/06/2025 | 01/01/2025 |
|--|-----------------------|------------------------|
| | VND | VND |
| - Non-term bank deposits | 14,275,558,425 | 10,636,771,380 |
| - Term deposits of no more than 3 months (*) | 22,000,000,000 | 175,900,000,000 |
| | 36,275,558,425 | 186,536,771,380 |

(*): Term deposits from 01 to 03 months at Vietnam Joint Stock Commercial Bank for Industry and Trade - Quang Trung Branch, interest rate from 4.1% to 4.5% per annum.

6. SHORT-TERM FINANCIAL INVESTMENTS

These are term deposits from 06 to 12 months at Vietnam Joint Stock Commercial Bank for Industry and Trade - Quang Trung Branch, interest rate from 4.8% to 5.3% per annum.

VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

INTERIM SEPARATE FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)*(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)***7. SHORT-TERM TRADE RECEIVABLES**

| | 30/06/2025 | | 01/01/2025 | |
|---|------------------------|-------------------------|------------------------|-------------------------|
| | Balance | Provision | Balance | Provision |
| | VND | VND | VND | VND |
| - Phat Nhu Quan Pharmaceutical Company Limited | 30,682,293,032 | (30,682,293,032) | 30,682,293,032 | (30,682,293,032) |
| - Thy Thu Pharmaceutical Company Limited | 8,962,462,619 | - | 28,121,999,397 | - |
| - BV Pharma Joint Stock Company | 25,625,540,221 | - | 25,542,126,659 | - |
| - Viet Nam Pharmaceutical and Trading Joint Stock Company | 18,574,103,597 | (18,574,103,597) | 18,574,103,597 | (18,574,103,597) |
| - Vinpharco Medical Joint Stock Company | 13,637,924,769 | (13,023,567,825) | 13,637,924,769 | (13,023,567,825) |
| - Ngoc Linh TM Medicine Company Limited | 16,776,318,532 | (16,630,107,729) | 16,776,318,532 | (16,630,107,729) |
| - Other receivables from customers | 71,583,437,937 | (3,656,907,979) | 52,571,685,497 | (3,656,907,979) |
| | 185,842,080,707 | (82,566,980,162) | 185,906,451,483 | (82,566,980,162) |
| | 245,204,150 | | 569,737,164 | |

Short-term trade receivables from related parties*(Details stated in Note 32)***8. SHORT-TERM ADVANCES TO SUPPLIERS**

| | 30/06/2025 | | 01/01/2025 | |
|--|----------------------|---------------------|----------------------|---------------------|
| | Balance | Provision | Balance | Provision |
| | VND | VND | VND | VND |
| - Minh Long Technological and Commercial Company Limited | 2,056,000,000 | - | 2,056,000,000 | - |
| - I-CODI Co., Ltd | 1,348,779,000 | - | 1,348,779,000 | - |
| - Other suppliers | 3,397,766,353 | (95,577,000) | 3,913,559,859 | (95,577,000) |
| | 6,802,545,353 | (95,577,000) | 7,318,338,859 | (95,577,000) |

Short-term advances to related parties*(Details stated in Note 32)*

VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

INTERIM SEPARATE FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)*(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)***9. OTHER RECEIVABLES**

| | 30/06/2025 | | 01/01/2025 | |
|--|------------------------|------------------------|------------------------|------------------------|
| | Balance | Provision | Balance | Provision |
| | VND | VND | VND | VND |
| Short-term | 149,740,083,512 | (1,833,524,819) | 146,805,738,445 | (1,833,524,819) |
| - Receivables from advances to resigned employees | 1,796,561,414 | (1,796,561,414) | 1,796,561,414 | (1,796,561,414) |
| - Receivables from BV Pharma Joint Stock Company (*) | 141,525,565,187 | - | 141,525,565,187 | - |
| - Advances for employees | 194,940,318 | - | 193,094,907 | - |
| - Accrued interest | 3,093,443,836 | - | 221,493,151 | - |
| - Other receivables | 3,129,572,757 | (36,963,405) | 3,069,023,786 | (36,963,405) |
| Long-term | 5,714,576,965 | - | 5,714,576,965 | - |
| - Long-term mortgages, collateral, deposits | 5,714,576,965 | - | 5,714,576,965 | - |
| | 155,454,660,477 | (1,833,524,819) | 152,520,315,410 | (1,833,524,819) |
| Other receivables from related parties | 1,235,471,069 | - | 1,232,471,069 | - |
| <i>(Details stated in Note 32)</i> | | | | |

(*): According to the Minutes of the Board of Management's meeting No. 07/2023/BB-VMD dated 13 March 2023 of Vimedimex Medi-Pharma Joint Stock Company on debt settlement of BV Pharma Joint Stock Company: temporarily holding the area according to the investment rate of the group of investors, BV Pharma Joint Stock Company and relatives of the Chairman of the Board of Management of BV Pharma Joint Stock Company, Mr. Nguyen Tien Hung, who has not yet contributed capital at Citilight building, 45 Vo Thi Sau, District 1 (old), Ho Chi Minh City until BV Pharma Joint Stock Company has paid all debts to Vimedimex Medi-Pharma Joint Stock Company.

VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

INTERIM SEPARATE FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

10. INVENTORIES

| | 30/06/2025 | | 01/01/2025 | |
|--------------------|----------------------|----------------------|----------------------|----------------------|
| | Historical cost | Provision | Historical cost | Provision |
| | VND | VND | VND | VND |
| - Raw materials | 97,112,500 | (97,112,500) | 97,112,500 | (97,112,500) |
| - Work in progress | 179,533,349 | (179,533,245) | 179,533,349 | (179,533,245) |
| - Goods | 9,104,325,941 | (48,452,423) | 9,104,325,941 | (48,452,423) |
| | 9,380,971,790 | (325,098,168) | 9,380,971,790 | (325,098,168) |

11. TANGIBLE FIXED ASSETS

| | Buildings and structures | Machinery and equipment | Motor vehicles | Office equipment | Perennial garden | Others | Total |
|---------------------------------|--------------------------|-------------------------|----------------------|----------------------|--------------------|----------------------|-----------------------|
| | VND | VND | VND | VND | VND | VND | VND |
| COST | | | | | | | |
| 01/01/2025 | 16,726,425,586 | 4,739,336,906 | 4,206,911,322 | 4,765,817,150 | 152,810,137 | 2,905,501,433 | 33,496,802,534 |
| 30/06/2025 | 16,726,425,586 | 4,739,336,906 | 4,206,911,322 | 4,765,817,150 | 152,810,137 | 2,905,501,433 | 33,496,802,534 |
| ACCUMULATED DEPRECIATION | | | | | | | |
| 01/01/2025 | 14,494,012,016 | 4,372,475,624 | 4,011,717,291 | 4,763,468,237 | 152,810,137 | 2,846,141,517 | 30,640,624,822 |
| - Depreciation | 176,462,418 | 51,729,044 | 40,839,240 | 2,348,913 | - | 9,286,446 | 280,666,061 |
| 30/06/2025 | 14,670,474,434 | 4,424,204,668 | 4,052,556,531 | 4,765,817,150 | 152,810,137 | 2,855,427,963 | 30,921,290,883 |
| CARRYING AMOUNT | | | | | | | |
| 01/01/2025 | 2,232,413,570 | 366,861,282 | 195,194,031 | 2,348,913 | - | 59,359,916 | 2,856,177,712 |
| 30/06/2025 | 2,055,951,152 | 315,132,238 | 154,354,791 | - | - | 50,073,470 | 2,575,511,651 |

The cost of tangible fixed assets as at 30 June 2025 that have been fully depreciated but are still in use: VND 22,655,903,070 (as at 01 January 2025: VND 22,238,896,570)

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

12. INTANGIBLE FIXED ASSETS

| Items | Land use rights | Copyright, computer software | Total |
|---------------------------------|-----------------|------------------------------------|----------------|
| | VND | VND | VND |
| COST | | | |
| 01/01/2025 | 21,279,738,169 | 1,697,374,990 | 22,977,113,159 |
| 30/06/2025 | 21,279,738,169 | 1,697,374,990 | 22,977,113,159 |
| ACCUMULATED AMORTIZATION | | | |
| 01/01/2025 | 5,654,122,232 | 1,697,374,990 | 7,351,497,222 |
| - Amortization | 232,473,402 | - | 232,473,402 |
| 30/06/2025 | 5,886,595,634 | 1,697,374,990 | 7,583,970,624 |
| CARRYING AMOUNT | | | |
| 01/01/2025 | 15,625,615,937 | - | 15,625,615,937 |
| 30/06/2025 | 15,393,142,535 | - | 15,393,142,535 |

The cost of intangible assets as at 30 June 2025 that have been fully amortized but are still in use: VND 1,697,374,990 (as at 01 January 2025: VND 1,697,374,990)

13. INVESTMENT PROPERTIES

| | Land use rights | Buildings and structures | Total |
|---------------------------------|-----------------|-----------------------------|-----------------|
| | VND | VND | VND |
| COST | | | |
| 01/01/2025 | 59,568,178,831 | 43,759,033,257 | 103,327,212,088 |
| 30/06/2025 | 59,568,178,831 | 43,759,033,257 | 103,327,212,088 |
| ACCUMULATED DEPRECIATION | | | |
| 01/01/2025 | 16,155,560,193 | 26,429,354,270 | 42,584,914,463 |
| - Depreciation | 658,211,920 | 807,777,500 | 1,465,989,420 |
| 30/06/2025 | 16,813,772,113 | 27,237,131,770 | 44,050,903,883 |
| CARRYING AMOUNT | | | |
| 01/01/2025 | 43,412,618,638 | 17,329,678,987 | 60,742,297,625 |
| 30/06/2025 | 42,754,406,718 | 16,521,901,487 | 59,276,308,205 |

Investment properties comprise a portion of the building and the land use rights located at 246 Cong Quynh Street, District 1 (former), Ho Chi Minh City, and the building at 45 Vo Thi Sau Street, Da Kao Ward, District 1 (former), Ho Chi Minh City, which are being leased out.

The Company has not determined the fair value of the investment properties as at the end of the reporting period because the current regulations do not provide specific guidance on the determination of the fair value of investment properties.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

14. CONSTRUCTION IN PROGRESS

| | 30/06/2025 | 01/01/2025 |
|--|-----------------------|-----------------------|
| | VND | VND |
| Fixed Asset Purchase | 1,060,000,000 | 1,060,000,000 |
| - System software development | 1,060,000,000 | 1,060,000,000 |
| Basic construction | 32,446,151,377 | 31,692,816,333 |
| - Project 18 Hoang Van Thu, Da Lat (*) | 27,637,379,453 | 26,884,044,409 |
| - Transaction Office Project in Can Tho City | 4,604,803,168 | 4,604,803,168 |
| - International Pharmaceutical TTPP Project in Da Nang | 203,968,756 | 203,968,756 |
| | 33,506,151,377 | 32,752,816,333 |

(*): Investment project to build the Research Center for Conservation and Development of Medicinal Herbs in the Central Highlands at No. 18 Hoang Van Thu, Ward 5, Da Lat City, Lam Dong Province (now No. 18 Hoang Van Thu, Cam Ly Ward - Da Lat, Lam Dong Province) according to the Investment and Business Cooperation Contract signed between the Company and Thao Nguyen Real Estate Investment Joint Stock Company ("Thao Nguyen"). The project is implemented on an area of 51,523.99 m2 with the goal of conserving and developing Medicinal Herbs in the Central Highlands, building a facility for accommodation to serve Organizations/Individuals who want to come to research, visit, and relax to introduce the model of conservation and development of Medicinal Herbs, and develop agricultural tourism.

According to the terms of the business cooperation contract, the Company represents the parties as the Investor. The Company's capital contribution is all assets attached to the land plot and contributes as the Project Investor. Thao Nguyen contributes the entire amount of money needed to establish and implement the Project. The cooperation profit will be divided between each party as follows: The Company receives 10% and Thao Nguyen receives 90% of the cooperation profit.

According to the agreement between the two parties, all investment costs for the Project construction and other costs arising in case the Project is not approved by the competent State agency or the project is not operated effectively will be borne by Thao Nguyen. At the time of preparing this separate financial report, the Project is still in the investment preparation stage.

VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

INTERIM SEPARATE FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

15. LONG-TERM INVESTMENTS

| | 30/06/2025 | | | 01/01/2025 | | |
|--|------------------------|-------------------------|-------------------|------------------------|-------------------------|-------------------|
| | Historical cost VND | Provision VND | Fair value VND | Historical cost VND | Provision VND | Fair value VND |
| <i>Investments in subsidiaries</i> | 207,027,132,620 | - | - | 207,027,132,620 | - | - |
| - Vimedimex Pharmaceutical Distribution Center - Company Limited | 92,027,132,620 | - | (*) | 92,027,132,620 | - | (*) |
| - Vimedimex Binh Duong One Member Company Limited | 50,000,000,000 | - | (*) | 50,000,000,000 | - | (*) |
| - Vimedimex Pharmaceutical Company Limited | 65,000,000,000 | - | (*) | 65,000,000,000 | - | (*) |
| <i>Investment in other entities</i> | 18,730,978,694 | (10,799,722,346) | - | 18,730,978,694 | (10,799,722,346) | - |
| - Vietnam Investment and Service Import Export JSC | 2,185,000,000 | - | (*) | 2,185,000,000 | - | (*) |
| - BV Pharma Joint Stock Company | 10,799,722,346 | (10,799,722,346) | (*) | 10,799,722,346 | (10,799,722,346) | (*) |
| - Nature Viet Nam Pharmaceutical Joint Stock Company (**) | 5,746,256,348 | - | (*) | 5,746,256,348 | - | (*) |
| | 225,758,111,314 | (10,799,722,346) | | 225,758,111,314 | (10,799,722,346) | |

(*): The Company has not determined the fair value as at the end of the financial year because the current regulations do not provide specific guidance on the determination of the fair value of financial investments. The fair value of these investments may differ from their carrying amounts.

(**): On 15 July 2019, the Board of Management of Vimedimex Medi-Pharma Joint Stock Company approved the transfer of shares in Nature Vietnam Pharmaceutical Joint Stock Company ("Nature Pharma") to Ms. Mai Thuy Linh, under the Share Transfer Agreement No. 01/2019/HĐCN dated 17 July 2019, with a total of 570,000 shares. Accordingly, the Company entered into a contract to transfer 570,000 shares of Nature Pharma to Ms. Mai Thuy Linh for a total value of VND 5,700,000,000.

As of 30 June 2025, Ms. Mai Thuy Linh had paid VND 4,700,000,000 in accordance with the share transfer agreement, while the remaining VND 1,000,000,000 had not yet been settled. Therefore, the Company has not completed the additional share transfer procedures. Consequently, as at the date of preparation of these separate financial statements, the Company continues to recognize its investment in Nature Vietnam Pharmaceutical Joint Stock Company as an investment in another entity.

VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

INTERIM SEPARATE FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)*(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)***15. LONG-TERM INVESTMENTS (CONT'D)****Detailed information about subsidiaries of the Company as at 30 June 2025 is as follows:**

| Name | Establishment and operation address | Ownership ratio | Voting rights ratio | Main operation field |
|--|-------------------------------------|-----------------|---------------------|--|
| Vimedimex Pharmaceutical Company Limited | Ho Chi Minh City | 100.0% | 100.0% | Wholesale of pharmaceutical products, modern medicine, functional foods, medical equipment, cosmetics, consumer goods for mothers and babies |
| Vimedimex Pharmaceutical Distribution Center - Company Limited | Hanoi | 55.6% | 55.6% | Wholesale, retail of pharmaceutical products, business cooperation, medical examination and treatment |
| Vimedimex Herbal One Member Limited Company | Da Lat | 100.0% | 100.0% | Growing medicinal herbs |

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

16. SHORT-TERM TRADE PAYABLES

| | 30/06/2025 VND | 01/01/2025 VND |
|---|------------------------|------------------------|
| - Mi Pharma Private Limited | 15,457,922,251 | 15,344,420,025 |
| - Vimedimex Binh Duong One Member Company | 11,802,899,011 | 12,422,392,114 |
| - IDS Medical Systems Vietnam Company Limited | 6,835,495,000 | 6,835,495,000 |
| - Ta Thien An Service Trading Company Limited | 5,972,913,418 | 5,972,913,418 |
| - Others | 195,020,507,075 | 179,259,818,333 |
| | 235,089,736,755 | 219,835,038,890 |
| Short-term trade payables to related parties <i>(Details stated in Note 32)</i> | 12,426,464,432 | 13,137,560,020 |

17. SHORT-TERM ADVANCES FROM CUSTOMERS

| | 30/06/2025 VND | 01/01/2025 VND |
|---|------------------------|------------------------|
| - Vimedimex Binh Duong One Member Company Limited | 160,419,045,131 | 160,419,045,131 |
| - An Khang Store | 3,600,177,236 | 3,600,177,236 |
| - Others | 2,840,073,108 | 2,854,132,452 |
| | 166,859,295,475 | 166,873,354,819 |
| Short-term advances from related parties <i>(Details stated in Note 32)</i> | 160,419,045,131 | 160,419,045,131 |

18. SHORT-TERM ACCRUED EXPENSES

| | 30/06/2025 VND | 01/01/2025 VND |
|-----------------------------|--------------------|----------------------|
| - Fixed asset repair costs | 482,779,966 | 482,779,966 |
| - Audit costs | 315,000,000 | 650,000,000 |
| - Other short-term payables | 142,138,917 | 116,300,031 |
| | 939,918,883 | 1,249,079,997 |

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

19. OTHER SHORT-TERM PAYABLES

| | 30/06/2025 | 01/01/2025 |
|---|-----------------------|-----------------------|
| | VND | VND |
| Short-term | 50,206,558,754 | 47,352,746,236 |
| - Union fees | 13,457,950 | 1,973,950 |
| - Social insurance | 32,068,449 | 32,068,449 |
| - Accept short-term deposits and bets | 5,916,857,640 | 5,916,857,640 |
| - BV Pharma Joint Stock Company (1) | 10,799,722,346 | 10,799,722,346 |
| Thao Nguyen Real Estate Investment Joint Stock | 8,500,000,000 | 8,500,000,000 |
| - Company (2) | | |
| - Thang Long Cargo Services Joint Stock Company (3) | 6,000,000,000 | 6,000,000,000 |
| - Ms. Mai Thuy Linh (4) | 4,700,000,000 | 4,700,000,000 |
| - Vimedimex Binh Duong One Member Company Limited | 4,299,680,020 | 4,299,685,051 |
| - Hoa Binh Securities Joint Stock Company (5) | 6,226,043,788 | 2,888,946,629 |
| - Others | 3,718,728,561 | 4,213,492,171 |
| Long-term | 18.713.053.167 | 17.643.092.392 |
| - Accept long-term deposits and bets | 18.664.613.167 | 17.594.652.392 |
| - Others | 48.440.000 | 48.440.000 |
| | 68,919,611,921 | 5,950,900,039 |
| Other short-term payables to related parties | 10,525,728,839 | 7,188,631,680 |

(Details stated in Note 32)

(1) The amount of money transferred by BV Pharma Joint Stock Company but the two parties have not yet agreed on the debt content to be offset with this payment amount. (Refer to Note 9).

(2) The amount of money for business cooperation with Thao Nguyen Real Estate Joint Stock Company to implement the project of Research Center for Conservation and Development of Western Highlands Medicinal Herbs at No. 18 Hoang Van Thu Street, Da Lat, Lam Dong - now No. 18 Hoang Van Thu, Cam Ly Ward - Da Lat, Lam Dong Province - (project details in Note 14).

(3) The amount of money for business cooperation received from Thang Long Goods Services Joint Stock Company ("Thang Long") under the Business Cooperation Contract No. 37/HTDT/2017 dated 11 January 2017 regarding business at No. 53 Nguyen Chi Thanh Street, Ward 9, District 5, Ho Chi Minh City (now An Dong Ward, Ho Chi Minh City). Accordingly, the two parties agreed to cooperate in investing in the construction of a system of office buildings and serviced apartments, the Company contributed capital with assets on land at plot 53 Nguyen Chi Thanh as well as rights and obligations attached to the plot of land, Thang Long contributed capital with the entire investment cost of upgrading and constructing the system of office buildings and serviced apartments.

(4) Amount of money received for the transfer of shares at Nature Vietnam Pharmaceutical Joint Stock Company from Ms. Mai Thuy Linh. Ms. Mai Thuy Linh has not paid the full value of the transfer contract, so the procedures for transferring shares have not been completed (Refer to Note 15).

(5) Profits distributed to Hoa Binh Securities Joint Stock Company related to Investment Real Estate is a part of Vimedimex Office Building at 246 Cong Quynh, Pham Ngu Lao Ward, District 1 (old), Ho Chi Minh City. This is an asset formed from the capital contribution contract for the construction of Vimedimex Office Building No. 022/2009/HD-VM-HBS between Hoa Binh Securities Joint Stock Company and Vimedimex Medi-Pharma Joint Stock Company.

VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

INTERIM SEPARATE FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)*(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)***20. TAX AND OTHER PAYABLES TO/RECEIVABLES FROM THE STATE BUDGET**

| | 01/01/2025 | Payable | Paid/Deducted | 30/06/2025 |
|-----------------------------|----------------------|-----------------------|-----------------------|----------------------|
| | VND | VND | VND | VND |
| Payables | | | | |
| - Output VAT | - | 5,257,888,169 | 5,257,888,169 | - |
| - Corporate income tax | 2,183,606,385 | 1,934,776,164 | 2,294,591,988 | 1,823,790,561 |
| - Personal income tax | 696,206,463 | 362,518,014 | 1,025,570,390 | 33,154,087 |
| - Property tax, land rental | - | 4,960,436,404 | 4,960,436,404 | - |
| | 2,879,812,848 | 12,515,618,751 | 13,538,486,951 | 1,856,944,648 |

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

21. OWNERS' EQUITY

21.1 OWNER'S EQUITY TRANSACTIONS

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|----------------------|---|---|
| Share capital | | |
| + Opening equity | 154,402,680,000 | 154,402,680,000 |
| + Closing capital | 154,402,680,000 | 154,402,680,000 |

21.2 SHARE

| | 30/06/2025 Share | 01/01/2025 Share |
|--|---------------------|---------------------|
| - Number of shares registered for issuance | 15,440,268 | 15,440,268 |
| - Number of shares sold in public market | 15,440,268 | 15,440,268 |
| + Common shares | 15,440,268 | 15,440,268 |
| - Number of shares outstanding | 15,440,268 | 15,440,268 |
| + Common shares | 15,440,268 | 15,440,268 |

* Par value of shares outstanding (VND 10,000/share)

21.3 FUNDS

| | 30/06/2025 VND | 01/01/2025 VND |
|--------------------------------|-------------------|-------------------|
| - Development investment funds | 29,732,320,126 | 29,732,320,126 |
| - Other funds | 7,338,446,765 | 7,338,446,765 |

VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

INTERIM SEPARATE FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

21. OWNER'S EQUITY (CONT'D)

21.4 STATEMENT OF CHANGES IN EQUITY

| Items | Share capital | Share premium | Development and investment fund | Other equity funds | Retained earnings | Total |
|------------------------|-----------------|-----------------|---------------------------------|--------------------|-------------------|------------------|
| | VND | VND | VND | VND | VND | VND |
| 01/01/2024 | 154,402,680,000 | 114,168,390,910 | 29,732,320,126 | 7,338,446,765 | 28,054,361,694 | 333,696,199,495 |
| - Profit in year | - | - | - | - | 21,721,522,002 | 21,721,522,002 |
| - Dividends | - | - | - | - | (30,880,536,000) | (30,880,536,000) |
| 31/12/2024 | 154,402,680,000 | 114,168,390,910 | 29,732,320,126 | 7,338,446,765 | 18,895,347,696 | 324,537,185,497 |
| 01/01/2025 | 154,402,680,000 | 114,168,390,910 | 29,732,320,126 | 7,338,446,765 | 18,895,347,696 | 324,537,185,497 |
| - Profit in the period | - | - | - | - | 7,504,649,030 | 7,504,649,030 |
| 30/06/2025 | 154,402,680,000 | 114,168,390,910 | 29,732,320,126 | 7,338,446,765 | 26,399,996,726 | 332,041,834,527 |

On 26 June 2025, pursuant to Resolution No. 01/2025/NQ-ĐHĐCĐ-VMD of the General Meeting of Shareholders of Vimedimex Medi-Pharma Joint Stock Company, the General Meeting issued a resolution to revoke 2,284,950 VMD shares, representing 14.8% of the charter capital of Vimedimex Medi-Pharma Joint Stock Company, and to cancel the shareholder status of Ms. Nguyen Ngoc Dung, Ms. Tran Thi Doan Trang, and Mr. Tran Kien Cuong, effective from 1 January 2025. The resolution also confirmed the shareholder status of Vimedimex Pharmaceutical Group Joint Stock Company as the holder of 2,284,950 VMD shares, equivalent to 14.8% of the charter capital of Vimedimex Medi-Pharma Joint Stock Company, effective from 1 January 2025.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

22. OFF-BALANCE SHEET ITEMS

Outsourced assets

The company signs land lease contracts at:

- No. 53 Nguyen Chi Thanh Street, Ward 9, District 5, Ho Chi Minh City (now No. 53 Nguyen Chi Thanh Street, An Dong Ward, Ho Chi Minh City) for the purpose of production and business (office) from 2009 to 1 January 2046. The leased land area is 700.6 m². According to this contract, the Company must pay annual land rent until the contract expires according to current regulations of the State. However, the Company has authorized all rights and obligations related to this land to Thang Long Cargo Services Joint Stock Company (Details of Business Cooperation with Thang Long Company in Note 19).
- No. 45 Vo Thi Sau Street, Da Kao Ward, District 1 (old), Ho Chi Minh City with an area of 2,692 m², lease term until 31 December 2045 for use as a pharmaceutical trade center and office. According to this contract, the Company must pay annual land rent until the contract expires according to current regulations of the State.
- No. 18 Hoang Van Thu Street, Ward 5, Da Lat City, Lam Dong Province (now No. 18 Hoang Van Thu, Cam Ly Ward - Da Lat, Lam Dong Province) with a leased area of 51,523.99 m², lease term until 25 December 2055 for the Company's production and business activities. According to this contract, the Company must pay annual land rent until the contract expires according to current regulations of the State.
- Ta Nung Commune, Da Lat City, Lam Dong (now Cam Ly Ward - Da Lat, Lam Dong Province) with an area of 83,198.9 m² of specialized land and agricultural land, land lease term of 50 years from 3 December 1993. According to this contract, the Company must pay annual land rent from 26 March 2010 until the due date according to current regulations of the State.

The Company signs contracts to lease assets on land at:

- Renting a house and land at No. 36/212B Truong Tho Ward, Thu Duc District, Ho Chi Minh City (now Thu Duc Ward, Ho Chi Minh City) for office and business production purposes from 1 January 2023 to 31 December 2027 (5 (five) years) according to the Property and Land Lease Contract at No. 36/212B Truong Tho Ward, Thu Duc District (now Thu Duc Ward, Ho Chi Minh City) No. 075/HD-TT dated 25 April 2024. The area of the leased land is 11,064.4 m². The land rental price is fixed throughout the lease term.
- The Company signed a contract to lease State-owned property, Villa No. 18 Hoang Van Thu, Ward 5, Da Lat City (with a total usable area of 642.56 m² from 10 April 2019 to 10 April 2069 for repair and renovation for production and business purposes. The land rental price is adjusted every 5 years according to the price regulated by the Provincial People's Committee at the time of implementation of each new cycle.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

23. REVENUE FROM SALE OF GOODS AND RENDERING OF SERVICES

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|---|---|
| - Revenue from providing services and trading in investment real estate | 44,727,903,997 | 43,198,600,122 |
| | <u>44,727,903,997</u> | <u>43,198,600,122</u> |
| Revenue from related parties <i>(Details stated in Note 32)</i> | 339,419,750 | 248,868,592 |

24. COST OF GOODS SOLD

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|---|---|
| - Cost of providing services, real estate investment business | 24,845,684,316 | 26,116,584,389 |
| | <u>24,845,684,316</u> | <u>26,116,584,389</u> |

25. FINANCIAL INCOME

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|-----------------------------------|---|---|
| - Interest from deposits or loans | 4,020,907,007 | 1,855,139,707 |
| - Dividends, distributed profits | 172,500,000 | 402,500,000 |
| | <u>4,193,407,007</u> | <u>2,257,639,707</u> |

26. FINANCIAL EXPENSES

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|----------------------------|---|---|
| - Unrealized exchange loss | 3,019,868,847 | 4,016,655,835 |
| | <u>3,019,868,847</u> | <u>4,016,655,835</u> |

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

27. SELLING EXPENSES AND GENERAL AND ADMINISTRATIVE EXPENSES

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|---|---|---|
| Selling expenses | 6,167,555,882 | 7,172,262,483 |
| - Cost of raw materials, materials, tools, and equipment | 27,141,458 | 22,136,173 |
| - Employee costs | 1,078,602,400 | 1,445,634,188 |
| - Fixed asset depreciation costs | 46,167,365 | 80,330,423 |
| - Outsourcing service costs | 4,580,975,755 | 5,020,622,631 |
| - Other expenses in cash | 434,668,904 | 603,539,068 |
| General and administrative expenses | 5,534,618,375 | 4,740,089,275 |
| - Management staff costs | 1,848,410,524 | 2,231,352,755 |
| - Material cost management | 940,000 | 8,056,563 |
| - Fixed asset depreciation costs | 410,397,660 | 410,397,660 |
| - Taxes, fees, charges | 1,112,776,806 | 47,082,334 |
| - Outsourcing service costs | 427,284,125 | 518,081,416 |
| - Other expenses in cash | 1,734,809,260 | 1,525,118,547 |
| | 11,702,174,257 | 11,912,351,758 |
| General, administrative and selling expense from related parties | 984,619,786 | 1,083,081,764 |
| <i>(Details stated in Note 32)</i> | | |

28. OTHER INCOME

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|----------|---|---|
| - Others | 308,161,398 | 4,862,295 |
| | 308,161,398 | 4,862,295 |

29. OTHER EXPENSES

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|---|---|
| - Administrative fines and late payment | 4,535,906 | 66,103,046 |
| - Money to remedy the consequences of the case (*) | 217,783,882 | - |
| | 222,319,788 | 66,103,046 |

(*): The company paid the compensation for the consequences of the case at International Progress Joint Stock Company (AIC), Biotechnology Center according to Decision No. 2525/QDCTHADS of the Civil Judgment Enforcement Department dated 11 March 2025.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

30. OPERATING COST BY FACTOR

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|----------------------------|---|---|
| - Material expenses | 76,472,529 | 195,521,166 |
| - Fees and Charges | 1,112,776,806 | - |
| - Labor costs | 3,595,657,007 | 4,882,065,000 |
| - Fixed asset depreciation | 1,566,531,925 | 2,043,206,939 |
| - Outsourcing services | 12,813,629,430 | 14,930,019,345 |
| - Other expenses in cash | 17,382,790,876 | 15,978,123,697 |
| | 36,547,858,573 | 38,028,936,147 |

31. CURRENT CORPORATE INCOME TAX EXPENSE

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|---|---|---|
| Total accounting profit before CIT | 9,439,425,194 | 3,349,407,096 |
| Adjustment increases | 702,319,788 | 426,103,046 |
| - Late payment fines, administrative fines on taxes | 4,535,906 | 66,103,046 |
| - Remuneration for non-executive members of the Board of Management | 360,000,000 | 360,000,000 |
| - Other non-deductible expenses | 337,783,882 | - |
| Adjustment decreases | 467,864,160 | 402,500,000 |
| - Dividends distributed, profit shared | 172,500,000 | 402,500,000 |
| - Unusual income | 295,364,160 | - |
| Total taxable income for the period | 9,673,880,822 | 3,373,010,142 |
| Prior years' losses carried forward | - | - |
| Total taxable income for the period | 9,673,880,822 | 3,373,010,142 |
| Tax rate | 20% | 20% |
| Total current corporate income tax expense | 1,934,776,164 | 674,602,029 |

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

32. TRANSACTIONS AND BALANCES WITH RELATED PARTIES

Related parties other than members of the Board of Management, Board of General Directors and Board of Supervisors are as follows:

| | | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|----------------------------------|--|---|---|
| | Position | | |
| Board of Management | | 846,086,956 | 720,000,000 |
| - Mr. Le Xuan Tung | Chairman | 240,000,000 | 240,000,000 |
| - Mr. Trinh Thanh Giang | Vice Chairman | 240,000,000 | 240,000,000 |
| - Ms. Tran My Linh | Member | 120,000,000 | 120,000,000 |
| - Mr. Le Tien Dung | Member | 120,000,000 | 120,000,000 |
| - Mr. Le Tri Dung | Member | 120,000,000 | - |
| - Mr. Nguyen Minh Son | Member (Appointed on 26 June 2025) | 3,043,478 | - |
| - Mr. Nguyen Phan Trung Kien | Member (Appointed on 26 June 2025) | 3,043,478 | - |
| Board of General Director | | 632,140,200 | 400,000,000 |
| - Ms. Tran My Linh | General Director | 226,080,900 | 220,000,000 |
| - Ms. Do Thi Dong | Deputy General Director | - | - |
| - Mr. Be Cong Son | Deputy General Director | - | - |
| - Mr. Nguyen Bao Anh | Deputy General Director | 115,059,300 | 180,000,000 |
| - Mr. Le Tri Dung | Deputy General Director | 120,000,000 | - |
| - Mr. Nguyen Anh Tuan | Deputy General Director (Appointed on 07 March 2025) | 171,000,000 | - |
| Board of Supervisors | | 150,760,869 | 180,000,000 |
| - Mr. Tran Hung Cuong | Chief Supervisor (Dismissed on 26 June 2025) | 87,717,391 | - |
| - Mr. Doan Duc Giang | Member (Appointed on 24 July 2025) | 60,000,000 | 60,000,000 |
| - Mr. Nguyen Ba Tuan | Member (Dismissed on 26 June 2025) | - | 90,000,000 |
| - Ms. Pham Thi Thu Thao | Member (Dismissed on 28 June 2024) | - | 30,000,000 |
| - Mr. Truong Duy Phong | Member (Appointed on 26 June 2025) | 1,521,739 | - |
| - Ms. Nguyen Thanh Thanh Binh | Member (Appointed on 26 June 2025) | 1,521,739 | - |

Other parties related to the Company include:

| No. | Related party | Relationship |
|-----|--|----------------------------|
| 1 | Vimedimex 2 Pharmaceutical Joint Stock Company | Major shareholder |
| 2 | Vimedimex Pharmaceutical Distribution Center - Company Limited | Subsidiary |
| 3 | Vimedimex Binh Duong One Member Company Limited | Subsidiary |
| 4 | Vimedimex Pharmaceutical Company Limited | Subsidiary |
| 5 | Vietnam Investment and Service Import Export Joint Stock Company | Other investment companies |

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

| | | |
|---|--|----------------------------------|
| 6 | Vimedimex Group Pharmacy Corporation | Parties related to board members |
| 7 | Vimedimex Herbal One Member Limited Company | Parties related to board members |
| 8 | Vimedimex Hoa Binh Real Estate Company Limited | Parties related to board members |
| 9 | Hoa Binh Securities Joint Stock Company | Parties related to board members |

Transactions with related parties

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|---|---|
| Revenue from goods and services | 339,419,750 | 248,868,592 |
| - Vimedimex Pharmaceutical Distribution Center Co.,LTD | - | 238,257,629 |
| - Vimedimex Binh Duong One Member Co.,LTD | 339,419,750 | 10,610,963 |
| Purchase of goods and services | 984,619,786 | 1,083,081,764 |
| - Vimedimex Hoa Binh Real Estate Co.,LTD | 984,619,786 | 1,083,081,764 |
| Profit sharing Business cooperation | 6,226,043,788 | 5,051,841,066 |
| - Hoa Binh Securities JSC | 6,226,043,788 | 5,051,841,066 |

Balances with related parties

| | 30/06/2025 VND | 01/01/2025 VND |
|--|------------------------|------------------------|
| Short-term trade receivables | 245,204,150 | 569,737,164 |
| - Vimedimex Pharmaceutical Distribution Center Co.,LTD | 237,918,945 | 562,451,959 |
| - Vimedimex 2 Pharmaceutical JSC | 7,285,205 | 7,285,205 |
| Other short-term receivables | 1,235,471,069 | 1,232,471,069 |
| - Vimedimex Pharmaceutical Materials Co.,LTD | 1,235,471,069 | 1,232,471,069 |
| Short-term payables to suppliers | 12,426,464,432 | 13,137,560,020 |
| - Vimedimex Binh Duong One Member Co.,LTD | 11,802,899,011 | 12,422,392,114 |
| - Vimedimex Hoa Binh Real Estate Co.,LTD | 541,540,882 | 633,143,367 |
| - Vimedimex 2 Pharmaceutical JSC | 42,584,269 | 42,584,269 |
| - Vimedimex Pharmaceutical Co.,LTD | 39,440,270 | 39,440,270 |
| Short-term advance payment by buyer | 160,419,045,131 | 160,419,045,131 |
| - Vimedimex Binh Duong One Member Co.,LTD | 160,419,045,131 | 160,419,045,131 |
| Other short-term payables | 10,525,728,839 | 7,188,631,680 |
| - Hoa Binh Securities JSC | 6,226,043,788 | 2,888,946,629 |
| - Vimedimex Binh Duong One Member Co.,LTD | 4,299,685,051 | 4,299,685,051 |
| Receive deposits and bets | 142,762,500 | 396,562,500 |
| - Vimedimex Binh Duong One Member Co.,LTD | 142,762,500 | 396,562,500 |

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

33. EVENTS OCCURRING AFTER THE END OF THE ACCOUNTING PERIOD

As of 10 September 2025, the Ho Chi Minh City Stock Exchange (HOSE) issued Notice No. 1656/QĐ-SGDHCM, announcing the additional list of securities ineligible for margin trading, which included the VMD stock code.

According to the Minutes of the Board of Management's Meeting No. 15/2025/BBHDQT-VMD dated 20 September 2025 of Vimedimex Medi-Pharma Joint Stock Company, the Board of Management requested the Board of General Directors to work with relevant parties to clarify matters related to certain former employees of the Company who allegedly abused their positions and authority to misappropriate assets, causing losses to Vimedimex Pharmaceutical Group Joint Stock Company, a related party of the Company:

- The fund transfers from Vimedimex Pharmaceutical Group Joint Stock Company (VMG) through Vimedimex Medi-Pharma Joint Stock Company (VMD), followed by cash withdrawals and bank transfers, totalled VND 343,738,865,391 (from 15 April 2021 to 30 January 2023). In addition, VMD recorded a receivable from Ms. Nguyen Ngoc Dung amounting to VND 193 billion, representing cash withdrawn in 2022 but not yet repaid (According to the Minutes of the Board of Management's Meeting No. 136/2024/BB-VMG dated 31 December 2024 of VMG, the Board of Management of VMG approved that VMG would be responsible for recovering the doubtful receivable of VND 193 billion related to Ms. Nguyen Ngoc Dung on behalf of VMD, and consequently, VMD would no longer have any obligation to repay the VND 193 billion payable to VMG.);
- The total dividend amount related to Vimedimex Medi-Pharma Joint Stock Company's (VMD) shares for 2021 and 2022, recorded in the accounts of three individuals – Ms. Nguyen Ngoc Dung, Ms. Tran Thi Doan Trang, and Mr. Tran Kien Cuong – amounted to VND 6,512,107,500, which should have been returned to Vimedimex Pharmaceutical Group Joint Stock Company. However, these individuals allegedly appropriated VND 6,512,005,000 from their personal accounts during the period from 15 June 2021 to 9 December 2022, including: Mr. Tran Kien Cuong: VND 3,131,192,000, Ms. Nguyen Ngoc Dung: VND 1,080,062,000, Ms. Tran Thi Doan Trang: VND 2,300,751,000.
- Certain individuals in executive management positions at both VMG and VMD directed cash inflows and outflows totaling VND 252,353,295,174, and instructed Mr. Nguyen Tien Manh to withdraw VND 76,978,900,000, resulting in a total loss of VND 328,400,200,202 for VMG during the period from 19 April 2021 to 24 October 2024.

On 24 October 2025, the Ho Chi Minh City Stock Exchange (HOSE) issued Decision No. 968/QĐ-SGDHCM to suspend the trading of the shares of Vimedimex Medi-Pharma Joint Stock Company (stock code: VMD), effective from 31 October 2025.

34. OTHER INFORMATION

POTENTIAL ASSETS - POTENTIAL DEBT AT CITILIGHT BUILDING AT 45 VO THI SAU

During the pre-equitization period, Medical Import-Export Company No. II (the predecessor of Vimedimex Medi-Pharma Joint Stock Company) received capital contributions from various organizations and individuals ("the Investors") under business cooperation contracts to develop the Citilight Building Project, a pharmaceutical trading and office center located at 45 Vo Thi Sau Street, Da Kao Ward, District 1 (former), Ho Chi Minh City ("Citilight Building"). Upon completion and commencement of operation of the Citilight Building, the Company allocated floor areas to the Investors in accordance with the proportions stated in the business cooperation contracts, allowing the Investors to utilize or lease such areas. Accordingly, the Investors either directly managed and used their allocated areas, or authorized the Company to lease them out and, on a quarterly basis, received rental income corresponding to office rental proceeds after deducting management fees, land lease payments, property taxes, and insurance costs.

For the period from 01/01/2025 to 30/06/2025

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)

(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)

On 16 February 2020, the Board of Management of Vimedimex Medi-Pharma Joint Stock Company held a meeting to discuss matters related to the Citilight Building Project located at 45 Vo Thi Sau Street, Da Kao Ward, District 1 (former), Ho Chi Minh City, as documented in the Minutes of the Board of Management Meeting No. 03/2020/BB-VMD dated 16 February 2020. Based on the audited financial statements for the year ended 31 December 2007, the following information was presented:


- The total investment in the Citilight Building amounted to VND 96,843,227,279, of which the total capital contributed by individual and institutional investors under business cooperation contracts was VND 51,056,056,717, representing 52.72% of the total construction cost of the Citilight Building at 45 Vo Thi Sau.
- The total area temporarily handed over to the investors under business cooperation contracts is 6,498.2 square metres. The total usable floor area to which the investors are entitled, based on the actual investment cost of the building upon project finalisation, is 5,351.24 square metres, equivalent to 52.72% of the total area of the Citilight Building (10,150 square metres). Accordingly, the capital contributed by the investors is 17.65% less than the area they have received.

On 24 February 2020, Vimedimex Medi-Pharma Joint Stock Company issued Official Letter No. 1421/2020/CV-VMD providing official information to press agencies regarding the Citilight Building at 45 Vo Thi Sau Street. The letter stated that the Company had temporarily suspended all activities related to the payment of rental fees for commercial areas at the Citilight Building at 45 Vo Thi Sau Street, as well as other activities arising from the capital contribution process for the construction of the Building, in order to review the entire capital contribution process, settlement of construction costs, allocation of floor areas, management and operation, and profit distribution of the Citilight Building. As at 30 June 2025, the outstanding payable balance to the related investors amounted to VND 159,093,490,347 (VND 139,296,511,929 as at 1 January 2025).


At present, the Company and the investors have not yet reached an agreement on the aforementioned matters. Accordingly, this event may give rise to future economic benefits and/or obligations for the Company once the Company and the investors have resolved the outstanding issues relating to capital contribution, profit distribution, and management of the Citilight Building, in accordance with the prevailing laws and regulations.

35. COMPARATIVE FIGURES

The comparative figures of the interim separate financial statements are the figures on the Company's audited financial statements for the year ended 31 December 2024 and the reviewed interim separate financial statements for the period from 01 January 2024 to 30 June 2024.


Tran Thi Thanh Binh
Preparer


Nguyen Thi Thu Dung
Chief Accountant


Tran My Linh
General Director

